May 2025 in “International Journal of Trichology” Baricitinib may effectively treat sudden hair whitening and regrowth in some cases.
January 2022 in “Drugs of Today”
5 citations
,
September 2011 in “Bioorganic & Medicinal Chemistry Letters” Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.
13 citations
,
September 2022 in “Frontiers in immunology” Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
20 citations
,
June 2019 in “JAAD Case Reports” Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
4 citations
,
September 2024 in “BMC Cancer”
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
6 citations
,
December 2018 in “Ophthalmic Plastic and Reconstructive Surgery” Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)” Baricitinib is effective and safe for treating severe alopecia areata.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
6 citations
,
October 2014 in “International Journal of Molecular Sciences” Tanshinone IIA helps protect tissue from low oxygen damage by activating certain cell pathways.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology” Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
February 2020 in “Oncology Times” Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
September 2023 in “Journal of the American Academy of Dermatology” January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
April 2017 in “Journal of Investigative Dermatology” SB414 may be an effective treatment for atopic dermatitis by reducing swelling and bacterial infection.
2 citations
,
November 2024 in “AAPS PharmSciTech” Spanlastic formulations improve rivaroxaban's oral anticoagulation efficiency.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
29 citations
,
July 2012 in “The Journal of Sexual Medicine” Rats had lasting erectile problems after stopping a certain medication.
January 2013 in “Journal of Chengdu Medical College” Tolterodine Tartrate effectively treats overactive bladder symptoms.
59 citations
,
April 2016 in “Breast Cancer Research and Treatment” Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.
Baricitinib may effectively treat oral lichen planus.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
June 2021 in “European Urology”